Prelude Therapeutics (PRLD) Earnings Date & Reports

Prelude Therapeutics Incorp is a clinical stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs... Show more

Get AI intraday signals

A.I. Advisor

published Earnings

PRLD is expected to report earnings to rise 14.86% to -42 cents per share on May 13

Prelude Therapeutics PRLD Stock Earnings Reports

Q1'25

Est.

$-0.43

Q4'24

Beat

by $0.10

Q3'24

Beat

by $0.04

Q2'24

Missed

by $0.04

Q1'24

Beat

by $0.07

The last earnings report on March 10 showed earnings per share of -37 cents, beating the estimate of -47 cents. With 32.27K shares outstanding, the current market capitalization sits at 51.77M.

View a ticker or compare two or three

Compare

PRLD